满堂彩

Microbiology

來源 : 0916032     發布時間 :2018-03-07    瀏覽次數 :5455

科研特色(se)

近(jin)年來承(cheng)擔了近(jin)百項(xiang)(xiang)(xiang)國(guo)(guo)家(jia)自(zi)(zi)然(ran)科(ke)學基金重點(dian)項(xiang)(xiang)(xiang)目(mu)(mu)(mu)(mu)、863計(ji)劃項(xiang)(xiang)(xiang)目(mu)(mu)(mu)(mu)、新藥創制國(guo)(guo)家(jia)重大專(zhuan)項(xiang)(xiang)(xiang)、國(guo)(guo)家(jia)自(zi)(zi)然(ran)科(ke)學基金面上項(xiang)(xiang)(xiang)目(mu)(mu)(mu)(mu)、973計(ji)劃子(zi)課(ke)題(ti)、傳染病國(guo)(guo)家(jia)科(ke)技重大專(zhuan)項(xiang)(xiang)(xiang)子(zi)課(ke)題(ti)以(yi)及浙(zhe)江省自(zi)(zi)然(ran)科(ke)學基金和(he)重大橫(heng)向合作項(xiang)(xiang)(xiang)目(mu)(mu)(mu)(mu)。發表SCI論文500余(yu)篇,獲(huo)得(de)省部級科(ke)技成果獎(jiang)一等獎(jiang)2項(xiang)(xiang)(xiang)、二等獎(jiang)7項(xiang)(xiang)(xiang)以(yi)及國(guo)(guo)家(jia)發明專(zhuan)利(li)30余(yu)項(xiang)(xiang)(xiang),支(zhi)撐合作企業獲(huo)得(de)多項(xiang)(xiang)(xiang)國(guo)(guo)家(jia)新藥證書和(he)重點(dian)新產品(pin)。

本系(xi)有人獸(shou)共患病(bing)(bing)原(yuan)微(wei)(wei)生(sheng)(sheng)(sheng)(sheng)(sheng)物(wu)分(fen)子(zi)致(zhi)病(bing)(bing)機(ji)制(zhi)與(yu)新型疫(yi)苗、性傳(chuan)播病(bing)(bing)原(yuan)微(wei)(wei)生(sheng)(sheng)(sheng)(sheng)(sheng)物(wu)分(fen)子(zi)致(zhi)病(bing)(bing)機(ji)制(zhi)與(yu)新型疫(yi)苗、細菌(jun)耐藥與(yu)膜相(xiang)關分(fen)子(zi)致(zhi)病(bing)(bing)機(ji)制(zhi)、皰疹病(bing)(bing)毒分(fen)子(zi)致(zhi)病(bing)(bing)機(ji)制(zhi)和(he)新型抗(kang)病(bing)(bing)毒藥物(wu)、微(wei)(wei)生(sheng)(sheng)(sheng)(sheng)(sheng)物(wu)合成生(sheng)(sheng)(sheng)(sheng)(sheng)物(wu)學(xue)(xue)(xue)、微(wei)(wei)生(sheng)(sheng)(sheng)(sheng)(sheng)物(wu)制(zhi)藥、微(wei)(wei)生(sheng)(sheng)(sheng)(sheng)(sheng)物(wu)生(sheng)(sheng)(sheng)(sheng)(sheng)物(wu)信息學(xue)(xue)(xue)與(yu)組合藥物(wu)設(she)計、微(wei)(wei)生(sheng)(sheng)(sheng)(sheng)(sheng)物(wu)生(sheng)(sheng)(sheng)(sheng)(sheng)物(wu)催化(hua)與(yu)生(sheng)(sheng)(sheng)(sheng)(sheng)物(wu)轉化(hua)等9個PI團隊(dui),其中微(wei)(wei)生(sheng)(sheng)(sheng)(sheng)(sheng)物(wu)合成生(sheng)(sheng)(sheng)(sheng)(sheng)物(wu)學(xue)(xue)(xue)、病(bing)(bing)原(yuan)微(wei)(wei)生(sheng)(sheng)(sheng)(sheng)(sheng)物(wu)學(xue)(xue)(xue)等研究方向在學(xue)(xue)(xue)術領域內具有較好的影響。

教學特(te)色

(1)本科生(sheng)(sheng)課程:醫(yi)(yi)學(xue)微生(sheng)(sheng)物學(xue)、生(sheng)(sheng)物化學(xue)、醫(yi)(yi)學(xue)寄(ji)生(sheng)(sheng)蟲學(xue)、生(sheng)(sheng)物芯片原理及數據分析、生(sheng)(sheng)命科學(xue)與(yu)技術實驗等;

(2)留(liu)學本科生課程:Medical Microbiology、Medical Parasitology;

(3)研究生課(ke)程(cheng):分(fen)子(zi)病原生物(wu)(wu)(wu)學(xue)(xue)(xue)、病原生物(wu)(wu)(wu)學(xue)(xue)(xue)專題、微(wei)生物(wu)(wu)(wu)合成生物(wu)(wu)(wu)學(xue)(xue)(xue)、微(wei)生物(wu)(wu)(wu)生物(wu)(wu)(wu)信息學(xue)(xue)(xue)、微(wei)生物(wu)(wu)(wu)制藥工程(cheng)、細胞培養技(ji)術(shu)、生物(wu)(wu)(wu)技(ji)術(shu)制藥前(qian)沿。

研究生培養方(fang)向

(1)人獸共患病(bing)原(yuan)微(wei)生物分子致病(bing)機制與新型基因工程疫苗研發;

(2)性傳播病(bing)原微生物分子(zi)致病(bing)機(ji)制與新(xin)型疫苗研(yan)發;

(3)細菌耐藥與膜相關(guan)分子致病機制;

(4)皰疹病毒分(fen)子致病機制與(yu)新型抗(kang)病毒藥物研發;

(5)微生(sheng)(sheng)物合成生(sheng)(sheng)物學;

(6)微生物制藥;

(7)微生物(wu)生物(wu)信息學與組(zu)合(he)藥物(wu)設計;

(8)微生物(wu)生物(wu)催化(hua)與(yu)生物(wu)轉(zhuan)化(hua);

(9)微生物(wu)(wu)(wu)天然產物(wu)(wu)(wu)化學生物(wu)(wu)(wu)學。